Table 1.
Patients demographics
| Characteristic | Korean patients (n=74) |
|---|---|
| Sex | |
| Female | 42 (56.8) |
| Male | 32 (43.2) |
| Asian race | 74 (100) |
| HCV GT1b | 74 (100) |
| Age (years) | 55.0±11.0 |
| BMI (kg/m2) | 24.2±3.3 |
| Treatment history | |
| Treatment-naive | 70 (94.6) |
| Treatment-experienced | 4 (5.4) |
| Cirrhosis* | 25 (33.8) |
| HCV/HIV coinfection | 0 (0) |
| Baseline viral load | |
| >800,000 IU/mL | 54 (73.0) |
| >2,000,000 IU/mL | 34 (45.9) |
| IL28B genotype | |
| CC | 60 (81.1) |
| Non-CC | 14 (18.9) |
Values are presented as mean±standard deviation or n (%).
HCV, hepatitis C virus; GT, genotype; BMI, body mass index; HIV, human immunodeficiency virus.
*
In the original treatment studies, the presence of cirrhosis was defined as METAVIR F4 on liver biopsy within 24 months of enrollment, FibroScan® >12.5 kPa within 12 months of enrollment, or a combination of FibroTest® score >0.75 and aspartate aminotransferase:platelet ratio index >2.